Background Current influenza virus vaccines are effective when well matched to the
circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging …

Novel vaccine strategies include the so-called subunit vaccines, which encompass only the
part of the pathogen to which immune recognition results in protection. The high purity of …

After decades of slow progress, the last years have seen a rapid acceleration of the
development of adjuvanted vaccines which have lately been approved for human use …

The advent of mass vaccination has saved millions of human lives and revolutionized the
quality of life. Vaccination is currently one of the most cost effective ways of managing …

The need to enhance the immunogenicity of purified subunit antigens has prompted the
development of several new adjuvants. However, many of these new molecules have …

Influenza is a major cause of respiratory disease leading to hospitalization in young
children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be …

BACKGROUND: Adding adjuvants such as MF59® to influenza vaccines can enhance the
immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+) MF59] …

Adjuvants are essential components of most clinically used vaccines. This is because the
majority of nonliving vaccines are relatively poor inducers of adaptive immunity unless …

Elderly people and subjects with underlying chronic diseases are at increased risk for
influenza and related complications. Conventional influenza vaccines provide only limited …

Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has
sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine …